NCT02918214

Brief Summary

Sepsis induces a reversible systolic and diastolic cardiac dysfunction. The presence of a left ventricular (LV) diastolic dysfunction during septic shock could favor harmful volume overload. Recently, a meta-analysis suggested a negative prognostic role of LV diastolic dysfunction in septic patients (Od Ratio: 1.82; 95%CI: 1.12 - 2.97; p = 0.02) but its external validity is hampered by the numerous limits and the heterogeneity of the studies. To date, a pathophysiological link between LV diastolic dysfunction associated with septic shock and the water balance (reflecting volume overload) remains to establish. In addition, small size studies reported an excess of mortality in patients with septic shock who were diagnosed with a high cardiac output. However, no large cohort has yet confirmed the negative prognostic role of a hyperkinetic hemodynamic profile at the initial phase of septic shock.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
440

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Typical duration for all trials

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 27, 2016

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 28, 2016

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2019

Completed
Last Updated

March 19, 2026

Status Verified

March 1, 2026

Enrollment Period

2.7 years

First QC Date

September 27, 2016

Last Update Submit

March 16, 2026

Conditions

Keywords

Septic Shockechocardiographydiastolic dysfunctionTransthoracicTransesophagealhyperkinesiaprognosis

Outcome Measures

Primary Outcomes (1)

  • Survival

    Survival at one month

    Day 28

Secondary Outcomes (2)

  • Daily water balance

    Day 1 to Day 3

  • Cumulated water balances

    Day 4

Study Arms (1)

echocardiography

Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients will be recruited in the ICU but also in Emergency Departments if they present with septic shock before ICU admission

You may qualify if:

  • Patient hospitalized in ICU for septic shock:
  • Documented or highly suspected infection (clinically or microbiologically)
  • Causing an organ failure defined as an acute change in total SOFA score ≥ 2 points (baseline SOFA score can be assumed to be zero in the absence of pre-existing organ dysfunction)
  • And low blood pressure (sBP \< 90 mmHg or a decrease of more than 40 mmHg compared to baseline, or mBP \< 65 mmHg) despite a fluid loading of 30 mL/kg (except if clinical or radiological sign of pulmonary fluid overload) requiring vasopressor infusion to maintain mBP \> 65 mmHg
  • And lactate level \> 2 mmol/L
  • Patient older than 18 years old affiliated to the French Social Security
  • Non-opposition of the patient (or of its next-of-kin) to participate in the study

You may not qualify if:

  • Ongoing dobutamine or epinephrine infusion
  • Severe left valvular disease (severe stenosis, severe regurgitation ≥ grade 3)
  • Constrictive pericarditis (invalidate the mitral tissue Doppler imaging)
  • Pregnant women
  • Patient with estimated life expectancy \< 24h.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

University Hospital

Amiens, 80000, France

Location

University Hospital

Brest, 29200, France

Location

University Hospital

Limoges, 87042, France

Location

CHU de Nancy

Nancy, 54511, France

Location

CH d'Orleans

Orléans, 45000, France

Location

Aphp - Ambroise Paré

Paris, 75010, France

Location

CHU de Poitiers

Poitiers, 86021, France

Location

Felix Guyon Hospital

Saint-Denis, 97405, France

Location

University Hospital

Toulouse, 31000, France

Location

University Hospital

Tours, 37000, France

Location

Related Publications (1)

  • Vignon P, Charron C, Legras A, Musset F, Slama M, Prat G, Silva S, Vandroux D, Muller G, Levy B, Boissier F, Evrard B, Goudelin M, Mankikian S, Nay MA, Jabot J, Riu B, Bailly P, Maizel J, Leger J, Vieillard-Baron A; CRICS-TRIGGERSEP Network. Left ventricular diastolic dysfunction is prevalent but not associated with mortality in patients with septic shock. Intensive Care Med. 2025 Jan;51(1):94-105. doi: 10.1007/s00134-024-07748-2. Epub 2025 Jan 7.

MeSH Terms

Conditions

Shock, SepticHyperkinesis

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShockDyskinesiasNeurologic ManifestationsNervous System DiseasesSigns and Symptoms

Study Officials

  • Marine GOUDELIN, MD

    University Hospital, Limoges

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2016

First Posted

September 28, 2016

Study Start

January 1, 2017

Primary Completion

October 1, 2019

Study Completion

October 1, 2019

Last Updated

March 19, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations